Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM512 in atopic dermatitis
NCT07230483Phase 2Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CM512 in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started Dec 2025; status: recruiting.
02
Drugs
CM512
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07230483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230483.